Molecular alterations in NSCLC encompass mutations in the epidermal growth factor receptor (EGFR) and BRAF (specifically the V600E mutation) genes and the Kirsten rat sarcoma viral oncogene (KRAS); rearrangements in the anaplastic lymphoma kinase (ALK) gene and ROS proto-oncogene receptor tyrosine kinase 1 (ROS1); alterations in exon 14 of the mesenchymal-epithelial transition (MET) gene; and gene fusions involving neurotrophic receptor tyrosine kinase, among others (2, 4, 5). The gene discussed is ALK; the disease is non-small cell lung carcinoma.